Head to Head Contrast: Elicio Therapeutics (ELTX) vs. Its Rivals

Elicio Therapeutics (NASDAQ:ELTX) is one of 610 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its rivals? We will compare Elicio Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Earnings and Valuation

This table compares Elicio Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Elicio Therapeutics	N/A	-$39.57 million	-5.81
Elicio Therapeutics Competitors	$872.42 million	$61.46 million	-28.85

Elicio Therapeutics’ rivals have higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 12.3% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Elicio Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Elicio Therapeutics’ rivals have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Profitability

This table compares Elicio Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Elicio Therapeutics Competitors	-809.34%	-698.29%	-27.91%

Analyst Ratings

This is a summary of current recommendations for Elicio Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	0	3	1	2.80
Elicio Therapeutics Competitors	8615	13310	40658	1400	2.54

Elicio Therapeutics presently has a consensus target price of $20.25, indicating a potential upside of 45.27%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 64.84%. Given Elicio Therapeutics’ rivals higher possible upside, analysts plainly believe Elicio Therapeutics has less favorable growth aspects than its rivals.

Summary

Elicio Therapeutics rivals beat Elicio Therapeutics on 7 of the 13 factors compared.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.